Sweden
Gedea Biotech AB is a Swedish biotech startup founded in 2015, focusing on developing pHyph, an antibiotic-free treatment for bacterial vaginosis (BV). With a prevalence of 10-30% among women of childbearing age, BV is a common and distressing condition. The current standard treatment with antimicrobials has a high recurrence rate of 15-30% within 3 months. Gedea Biotech's pHyph offers a non-antimicrobial-based solution to treat the infection and prevent recurrence, addressing a critical need in women's health. At a crucial time when antimicrobial resistance is a top threat to global health, the company's research into novel non-antimicrobial based treatments is timely.
The startup secured a significant €2.50M grant investment from The European Innovation Council on 29 February 2024, underscoring the confidence in Gedea Biotech's groundbreaking approach to addressing BV. The company's dedication to offering an alternative to antimicrobial-based treatments in women's health has positioned it as a promising player in the biotechnology and healthcare industries.
